Prenatal exposure to second-generation antipsychotics (SGAs) did not increase risk of adverse childhood developmental or behavioral outcomes compared with antipsychotic-unexposed children, a study examining preschool-aged children has found. This was one of the largest studies to date that examined neurobehavioral outcomes in children exposed prenatally to SGAs, the investigators reported. Study results were published online March 13, 2024, in the Journal of Clinical Psychiatry.
A 40-week study has found that obese or overweight individuals with stable bipolar disorder who received liraglutide lost significantly more body weight than individuals receiving placebo. Liraglutide was associated with few adverse events and no exacerbation of psychopathology.
A cohort study examining both publicly and commercially insured individuals has found that prenatal exposure to topiramate or lamotrigine is associated with lower risk of childhood autism compared with exposure to valproate. Study results were largely unchanged in analyses limited to women who received the medications late in pregnancy. Results were published March 21/28, 2024, in The New England Journal of Medicine.
The standard pharmacological approach in psychiatric treatment, based on trial and error within a class of drug, often necessitates medication changes due to lack of efficacy or occurrence of adverse effects. The following case described how a more personalized pharmacogenetic approach could facilitate selection of effective treatment (Hudnik et al., 2024).
Selegiline transdermal system (generic) — Emsam (brand)
A systematic review and meta-analysis encompassing 15 clinical trials has concluded that pharmacogenomic-guided depression treatment results in a small improvement in antidepressant efficacy relative to treatment as usual. There was no difference in treatment discontinuation rates between pharmacogenomic-guided and conventional treatment.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：